Multistrain probiotics fail to modulate the asthmatic phenotype, respiratory microbiota, and immune responses in cats

• DOI: 10.2460/ajvr.23.12.0271
• Publication Date: 2024-05-22T12:50:47Z
• Authors: Julia D. Remaks; Aida I. Vientos-P...; Hansjorg Rindt; Zachary McAdams; Aaron C. Ericsson; Carol R. Reinero
• Keywords: Male; Probiotics; Microbiota; 0402 animal and dairy science; 04 agricultural and veterinary sciences; Cat Diseases; Asthma; Phenotype; Cats; Animals; Female; Bronchoalveolar Lavage Fluid; Glucocorticoids

Abstract

OBJECTIVE To determine if multistrain probiotics administered to asthmatic cats treated with anti-inflammatory glucocorticoids would attenuate the asthmatic phenotype and beneficially alter respiratory, blood, and oropharyngeal (OP) microbial communities and immune parameters versus placebo.

ANIMALS 13 client-owned asthmatic cats.

METHODS A randomized, blinded, placebo-controlled clinical trial of asthmatic cats receiving anti-inflammatory glucocorticoids with oral multistrain probiotics or placebo assessed owner-perceived improvement and airway eosinophilia at baseline and after 2 weeks of treatment. Bronchoalveolar lavage fluid (BALF), blood, OP, and rectal microbial communities were compared using 16S rRNA amplicon sequencing. Real-time PCR for transcription factors, activation markers and cytokines, and IgA ELISAs were evaluated. Statistical analyses used 2-way repeated-measures ANOVA or permutational ANOVA (significance, P < .05).

RESULTS After treatment, there were no significant differences in owner-perceived clinical signs or mean ± SEM BALF eosinophils between groups. There was a significant decrease in rectal α-diversity but not in α- or β-diversity in BALF, blood, or OP between groups or over time. There were no significant differences in CD25, FoxP3, GATA, Helios, IL-4, IL-5, IL-10, IL-13, IL-17, IFN-γ mRNA, or serum or BALF IgA between groups or over time.

CLINICAL RELEVANCE In asthmatic cats, oral multistrain probiotics failed to improve owner-perceived signs, reduce airway eosinophilia, modify microbial community composition, or alter assessed immune responses versus placebo or over time. Longer treatment, different probiotic composition or delivery (eg, aerosolized), or larger number of cats would represent the next stages of study.